In this retrospective study of 168 patients with acute myeloid leukemia in complete remission who underwent allogeneic HCT, five-year survival was significantly higher using unrelated donors ≤39 years compared to related donors >39 years: 66% vs. 34%, respectively (p=0.001). Median follow-up was 59 months and median donor age was 39 years. In a multivariate analysis, only donor age and cytogenetic risk affected five-year survival. Compared with unrelated donors ≤39 years, both related donors >39 years (relative risk (RR): 4.31; p=0.001) and unrelated donors >39 years (RR: 2.14; p=0.03) were associated with poorer five-year survival.
Better HCT Outcomes with Younger Unrelated Donors vs. Older Related Donors